H.C. Wainwright Reiterates Buy Rating on Enliven Therapeutics (ELVN)

April 8, 2026 7:12 AM

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $56.00 price target on Enliven Therapeutics (NASDAQ: ELVN).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found